Clinical Trials Logo

Clinical Trial Summary

This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04620655
Study type Interventional
Source Hebei Yanda Ludaopei Hospital
Contact Xian Zhang
Phone +86-13641041596
Email zhxian2@126.com
Status Recruiting
Phase N/A
Start date November 15, 2020
Completion date November 15, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02484430 - Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Phase 2
Terminated NCT03519984 - EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Phase 1
Recruiting NCT04128501 - Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Phase 2
Recruiting NCT04582487 - Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL N/A
Recruiting NCT00501826 - Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Phase 2
Withdrawn NCT02538926 - Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Phase 2
Active, not recruiting NCT00408005 - Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Phase 3
Terminated NCT02767934 - Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Phase 2
Withdrawn NCT06210750 - Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Phase 2
Recruiting NCT03007147 - Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Phase 3
Recruiting NCT05602194 - Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Phase 3
Recruiting NCT03504644 - Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2